Stockscreener 앱 받기
9.05
5.97%
0.51
시간 외 거래:
9.05
전일 마감가:
$8.54
열려 있는:
$8.69
하루 거래량:
1.34M
Relative Volume:
1.57
시가총액:
$466.95M
수익:
$676.80M
순이익/손실:
$-8.60M
주가수익비율:
-31.99
EPS:
-0.2829
순현금흐름:
$135.40M
1주 성능:
+9.96%
1개월 성능:
+9.96%
6개월 성능:
-12.48%
1년 성능:
+82.83%
1일 변동 폭
$8.67
$9.5401
1주일 범위
$7.5318
$9.5401
52주 변동 폭
$4.71
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, ZTS, TEVA, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.05 | 440.63M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com India
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director DeGolyer sells $129,993 in shares - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
MSN Money - MSN
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
Emergent BioSolutions Earnings Call Highlights Turnaround Momentum - The Globe and Mail
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer LINDAHL RICHARD S - Moomoo
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer PAPA JOSEPH C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Perl Jessica - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Hartzel William - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Lowry Simon C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Glessner Coleen - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved - MarketBeat
Emergent BioSolutions Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:EBS) 2026-05-02 - Seeking Alpha
Emergent BioSolutions Q1 2026 Financial Results: Earnings, Revenue, and Key Risk Factors Explained - Minichart
Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround - The Globe and Mail
Emergent BioSolutions (EBS) SVP awarded 100,111 restricted stock units under amended plan - Stock Titan
Emergent BioSolutions (EBS) awards 100,111 RSUs to R&D CMO - Stock Titan
Emergent BioSolutions (NYSE: EBS) awards 100,111 RSUs to EVP - Stock Titan
Emergent BioSolutions (EBS) CFO receives 162,680 restricted stock units - Stock Titan
Emergent BioSolutions (EBS) SVP awarded 104,282 restricted stock units - Stock Titan
SVP at Emergent BioSolutions (NYSE: EBS) receives 100,111 RSUs - Stock Titan
Emergent BioSolutions (NYSE: EBS) CEO gets 187,708 RSUs over 3 years - Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent (EBS) Q1 2026 Earnings Transcript - The Globe and Mail
Emergent Biosolutions Q1 2026 earnings preview - MSN
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Emergent Biosolutions Q1 Earnings Call Highlights - MarketBeat
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights - GuruFocus
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround - Investing.com Australia
Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround By Investing.com - Investing.com South Africa
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.67%
2.13%
자본화:
|
볼륨(24시간):